In primary human trabecular meshwork, Schlemm’s canal, and ciliary smooth muscle cultures, bimatoprost increased monolayer impedance with reported functional EC50 values of 4.3, 1.2, and 1.7 nM, respectively. These are assay-specific response potencies, rather than treatment concentrations or binding affinities. [1]
In perfused human donor anterior segments, 1 μM bimatoprost increased conventional outflow facility by 40% from baseline after 48 hours (10 segments). Antagonist co-treatment and pretreatment groups showed smaller descriptive responses. The experiment used active contralateral comparators and baseline controls; corneal thickness also increased during exposure and returned toward baseline after washout. [2]
Acute impedance responses in primary human ocular outflow cells
Cell-based study · Primary human trabecular meshwork (TM), Schlemm’s canal (SC), and ciliary smooth muscle (CSM) monolayers. [1]
Bimatoprost increased impedance in all three cell types. Buffer-only signals were subtracted; fluprostenol and 17-phenyl PGF2α served as FP-agonist comparisons. Cicaprost and U46619 established differential impedance responses in separate control exposures. Increased impedance is compatible with relaxation, but also reflects cell-contact changes, especially in SC.
Literature-Reported Treatment Conditions
- Treatment concentration
- Agonist concentration-response series; CDS methods state 1 pM–1 μM, while Figure 2 extends to 10 μM and normalization used 10 μM bimatoprost.
- Exposure duration
- 10 minutes of real-time recording after ligand addition
- Method
- Cellular dielectric spectroscopy (CellKey); baseline 2 minutes at 37°C
- Vehicle
- Hanks HEPES buffer with 0.1% BSA; buffer-only wells were controls.
- Reported limits
- Exact point-by-point dosing list and stock solvent are not specified in the adopted assay description.
Methods and source locations
Compound reported in the paper: Bimatoprost; Compound label in the paper: Bimatoprost
Results apply to the tested material and model; they do not establish performance of an Adooq lot.
Materials and Methods: Cell Culture, Chemicals, Cellular Dielectric Spectroscopy, Statistical Analysis; Results, Figures 1–2
Functional EC50 for increased monolayer impedance: Buffer-subtracted MAX−MIN impedance response; normalized to maximum bimatoprost response at 10 μM. Curves: mean ± SEM, three independent experiments using two strains per cell type as stated in caption. — Results paragraph preceding Figure 2; Figure 2 and caption; CDS and Statistical Analysis
Actin polymerization assay in human trabecular meshwork cells
Cell-based study · Mature primary human TM monolayers; two strains, n = 4 as reported. [1]
Bimatoprost decreased the F-actin/G-actin ratio, providing an orthogonal cellular readout consistent with the impedance-based relaxation interpretation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM
- Exposure duration
- 30 minutes
- Method
- Actin fractionation followed by immunoblot densitometry after 2-hour serum starvation
- Reported limits
- Methods describe untreated controls, while Results call them vehicle-treated; vehicle identity is not specified. The n = 4 unit is not further defined.
Methods and source locations
Compound reported in the paper: Bimatoprost; Compound label in the paper: Bimatoprost
Results apply to the tested material and model; they do not establish performance of an Adooq lot.
Materials and Methods: Filamentous/Globular Actin Assay; Results paragraph beginning “We validated CDS findings”
F-actin/G-actin ratio: Fractionated actin quantified by immunoblot densitometry; phalloidin-treated untreated lysate served as a positive fractionation control. Assay methods describe a two-tailed paired Student’s t-test “assuming unequal variance”; preserve this unusual wording without reconstructing analysis. — Results: actin validation paragraph; Filamentous/Globular Actin Assay
Conventional outflow facility in perfused human donor anterior segments
Cell-based study · Ex vivo human anterior segments: 20 segments from 11 donors, 49–91 years; 10 bimatoprost-only segments, 4 contralateral co-treatment segments, 6 antagonist-pretreated segments. [2]
Bimatoprost increased facility from each segment’s stable baseline. Antagonist co-treatment and pretreatment produced smaller descriptive changes. These controls were pharmacologically active, rather than a parallel untreated time control. Corneal thickness also increased during bimatoprost exposure and returned toward baseline after washout.
Literature-Reported Treatment Conditions
- Treatment concentration
- Bimatoprost 1 μM; AGN211334 30 μM in comparison segments
- Exposure duration
- 48-hour bimatoprost exposure; antagonist pretreatment 24 hours where applicable; fresh-medium washout afterward
- Method
- Constant-flow anterior segment organ perfusion at 2.5 μL/min; baseline stable for at least 24 hours before treatment
- Vehicle
- Ethanol stocks diluted into DMEM-based perfusion medium; final ethanol content not reported.
- Co-treatment
- Bimatoprost alone compared with concurrent AGN211334 plus bimatoprost, or AGN211334 pretreatment followed by both drugs.
- Reported limits
- No parallel vehicle-only segment arm in the adopted comparison. Donor-pair design and different antagonist schedules should not be treated as independent randomized drug-versus-vehicle arms.
Methods and source locations
Compound reported in the paper: Bimatoprost; Compound label in the paper: Bimatoprost
Results apply to the tested material and model; they do not establish performance of an Adooq lot.
Methods: Materials, Anterior Segment Perfusion Model, Central Corneal Thickness, Morphological Analysis, Statistical Analysis; Results: Bimatoprost and AGN211334 Effects on Outflow Facility and Bimatoprost and Central Corneal Thickness; Tables 2–3; Figures 2–3, 5
Change in conventional outflow facility from stable baseline in bimatoprost-only segments: (Cd−Co)/Co × 100%; reported group summaries mean ± SEM. Paired t-test; Methods threshold P < 0.01. Baseline facility 0.18 ± 0.04 μL/min/mmHg. — Results: facility summary; Table 3; Figure 3
Facility changes in antagonist comparison segments: Changes relative to original baseline. The source calls some P = 0.02–0.04 changes significant despite its P < 0.01 Methods threshold; no significance claim is adopted for those changes. — Results: facility summary; Table 3; Figures 2–3
Central corneal thickness during bimatoprost-only exposure: Pachymetry; source mean ± SEM. Report descriptive increase; P = 0.015 does not meet the stated P < 0.01 threshold. — Results: Bimatoprost and Central Corneal Thickness; Figure 5